CollPlant Biotechnologies Ltd. reported financial results for the second quarter and six-month period ended June 30, 2025. The company reported GAAP revenues of $179,000 for the second quarter of 2025, down from $249,000 in the same period of 2024. For the six months ended June 30, 2025, revenues stood at $2.2 million, a significant increase from $347,000 in the corresponding period of 2024. The company recorded a net loss of $4.8 million for the six months ended June 30, 2025, compared to a net loss of $8.4 million in the same period of the previous year. The basic and diluted net loss per ordinary share was $0.41 for the six-month period in 2025, compared to $0.73 in 2024. In terms of cash flow, CollPlant reported cash and cash equivalents of $11.4 million as of June 30, 2025. The cash used in operating activities for the first half of 2025 was $3.6 million, a decrease from $7.2 million in the first half of 2024. Cash used in investing activities was $11,000, down from $341,000 in the previous year, primarily due to reduced purchases of property and equipment. The company also saw a significant increase in cash provided by financing activities, reporting $3.1 million in the first half of 2025, up from $9,000 in the same period of 2024, mainly attributed to a registered direct offering. CollPlant continues to focus on expanding its market presence for its rhCollagen-based products and platforms. The company is encouraged by strong results from preclinical studies on regenerative breast implants and plans to share additional data on its photocurable product candidate in the coming months.